ICU Medical Q3 results beat estimates on Infusion Systems

Overview

• U.S. medical device maker's Q3 revenue rose yr/yr, beating analyst expectations

• Adjusted EPS for Q3 beat analyst expectations

• Company reaffirmed 2026 guidance, expects results at high end of range

Outlook

• ICU Medical expects FY 2026 results at high end of prior guidance range

• Company maintains FY 2026 GAAP net income guidance of $73 mln to $83 mln

• ICU Medical sees FY 2026 adjusted diluted EPS of $8.60 to $9.00

Result Drivers

• INFUSION SYSTEMS - Co said Q3 results were driven by better-than-expected performance in Infusion Systems

• PRODUCT LINE PERFORMANCE - Co reported yr/yr revenue growth in Consumables and Infusion Systems, offset by decline in Vital Care

• GROSS MARGIN IMPROVEMENT - Co attributed higher Q3 gross margin to improved product mix and operational efficiencies

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for ICU Medical, Inc. is $195.00, about 13% above its November 4 closing price of $172.62

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads

• Nov 5 - InfuSystem beats Q3 profit estimates on oncology, wound care growth

• Nov 5 - Teleflex Q3 revenue slightly beats estimates

• Nov 3 - Strata Critical Medical Q3 revenue beats estimates; announces buyback

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)